BIRC5 and neoplasm: When the entire survivin immunotherapy portfolio is assessed, most studies indicate that immunological responses can be generated against survivin, but it is unclear if the induced anti-survivin effector responses are maintained in the tumor microenvironment and if there is sufficient immune effector response distribution in the solid cancers that have been treated.